Further investigation using a neutralizing anti-PD-L1 antibody in vivo and dendritic cell-specific PD-L1 knockout mice revealed that PD-L1 expression on non-dendritic cells, including monocytes, is crucial for OM-MOG’s therapeutic impact. The gene discussed is MOG; the disease is ocular melanoma.